Jump to: navigation, search
Systematic (IUPAC) name
CAS number 117-10-2
ATC code A06AB03 A06AG03
PubChem 2950
DrugBank DB04816
Chemical data
Formula C14H8O4 
Mol. mass 240.211 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes Oral, rectal (enema)

WikiDoc Resources for Dantron


Most recent articles on Dantron

Most cited articles on Dantron

Review articles on Dantron

Articles on Dantron in N Eng J Med, Lancet, BMJ


Powerpoint slides on Dantron

Images of Dantron

Photos of Dantron

Podcasts & MP3s on Dantron

Videos on Dantron

Evidence Based Medicine

Cochrane Collaboration on Dantron

Bandolier on Dantron

TRIP on Dantron

Clinical Trials

Ongoing Trials on Dantron at Clinical Trials.gov

Trial results on Dantron

Clinical Trials on Dantron at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dantron

NICE Guidance on Dantron


FDA on Dantron

CDC on Dantron


Books on Dantron


Dantron in the news

Be alerted to news on Dantron

News trends on Dantron


Blogs on Dantron


Definitions of Dantron

Patient Resources / Community

Patient resources on Dantron

Discussion groups on Dantron

Patient Handouts on Dantron

Directions to Hospitals Treating Dantron

Risk calculators and risk factors for Dantron

Healthcare Provider Resources

Symptoms of Dantron

Causes & Risk Factors for Dantron

Diagnostic studies for Dantron

Treatment of Dantron

Continuing Medical Education (CME)

CME Programs on Dantron


Dantron en Espanol

Dantron en Francais


Dantron in the Marketplace

Patents on Dantron

Experimental / Informatics

List of terms related to Dantron

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Dantron (INN), also known as chrysazin or 1,8-dihydroxyanthraquinone, is an organic substance, formally derived from anthraquinone by the replacement of two hydrogen atoms by hydroxyl groups (–OH). It is used in some countries as a stimulant laxative.

It should not be confused with ondansetron, an unrelated drug that was marketed in South Africa under the trade name "Dantron".

Medical uses

In the USA, dantron is not used because it is considered to be a carcinogen.[1]

In the UK it is considered a possible carcinogen and so its licence is restricted to patients who already have a diagnosis of terminal cancer. It is mainly used in palliative care to counteract the constipating effects of opioids. Its British Approved Name was danthron, but it has now been changed to "dantron", the recommended International Nonproprietary Name.[2]

Dantron has the notable side-effect of causing red-colored urine.